Panovir is a fixed- cure combination antiviral drug containing Sofosbuvir( 400 mg) and Velpatasvir( 100 mg). Panovir is an oral drug generally used for the treatment of habitual hepatitis C contagion( HCV) infection in all six major genotypes( 1 – 6). It comes as a general drug to Epclusa. Panovir offers an affordable but largely effective form of treatment for cases floundering against long- term infections of HCV. Its potent binary- action system works to help viral replication, help liver damage, and ameliorate the liability of achieving a sustained virologic response( SVR), which is considered a cure.

Sofosbuvir is an NS5B polymerase asset nucleotide analogue of HCV. It's a prodrug that, formerly inside the body, gets metabolized into its active form, which mimics natural RNA structure blocks to replicate. Sofosbuvir causes hindrance with viral RNA objectification into viral replication by causing unseasonable termination when it becomes incorporated into viral RNA during replication.

Velpatasvir is an HCV NS5A asset that works by inhibiting the HCV replication complex. It blocks viral way necessary for RNA replication and assembly of the virion.

Together, both medicines are synergistic in inhibiting the contagion at multiple points in the life cycle of the contagion with performing strong antiviral exertion against all genotypes of HCV.

Panovir is applied in the treatment of

habitual HCV infection in adolescents and grown-ups( 12 times or aged or importing at least 35 kg)

All HCV genotypes( 1- 6), i.e., apan-genotypic treatment

Cirrhotic cases and those without cirrhosis

Cases with or without HIVco-infection

Cases with compensated or decompensated liver complaint, when administered with ribavirin in some cases

The lozenge of Panovir is one tablet once a day, orally, with or without food. The duration of treatment is generally

12 weeks in cases with or without decompensated cirrhosis

12 weeks plus Ribavirin in named cases with decompensated cirrhosis

Always follow the croaker 's guidance regarding lozenge, treatment duration, and any probative drug that must be administered.

Clinical trials have demonstrated that the Sofosbuvir- Velpatasvir combination has SVR( cure) rates above 95 in all genotypes and patient populations. This extremely high viral concurrence rate has made Panovir a treatment standard largely recommended in global HCV treatment guidelines, including those of WHO and AASLD.

Panovir is tolerable in cases. The most frequent side effects are

Fatigue

Headache

Nausea

Insomnia

Diarrhea

Severe side effects  are rare, but can include bradycardia when used with amiodarone, or exacerbation of liver failure in advanced complaint without monitoring.

The case should inform their healthcare provider of all specifics that are taken because Panovir can interact with rifampin, St. John's wort, and some antiretrovirals.

Not used in gestation when used with Ribavirin

Contraindicated in cases antipathetic to any element of the expression

Use with caution in those with end- stage renal complaint or with severe renal impairment, although more recent guidance is to use precisely with monitoring

Ought to be used under medical supervision, especially in cirrhosis cases orco-infected cases

Panovir is used considerably as a cheap general medicine in utmost developing nations, similar as Bangladesh, India, and Pakistan. Its affordability places it in the hands of further people, which, by far, has been the major donation towards the worldwide trouble to annihilate hepatitis C as a public health imminence.

Panovir( Sofosbuvir 400 mg Velpatasvir 100 mg) is a introducing oral rules of habitual hepatitis C with high cure rates,pan-genotypic content, and minimized dosing. With an excellent safety profile, simplified dosing, and global vacuity, Panovir has come a standard element of HCV operation. For cases taking a safe, reliable, and effective cure for hepatitis C, Panovir provides a novel and guaranteed remedial option with strong clinical substantiation and wide medical acceptance.